|Articles|September 24, 2015
Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer
Author(s)Lecia V. Sequist
Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).
Advertisement
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Breast Cancer Treatments Awaiting FDA Decisions: 4 to Watch
2
FDA Approves Etcamah Plus CDK4/6 Inhibitor for ESR1-Mutated Breast Cancer
3
Prostate Cancer Treatments in the FDA Pipeline: What Could Come Next
4
How AI Is Changing Breast Cancer Screening
5